Creative Biolabs provides customized support across key stages of lipid-based therapeutic development, helping researchers optimize delivery systems for different types of therapeutic payloads, ...

Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III ...

Shanghai Ark Biopharmaceutical Co., Ltd. ('ArkBio') today announced that the U.S. Food and Drug Administration (FDA) has approved ziresovir (AK0529) for a phase II clinical trial in the severely ill ...

Artificial intelligence (AI)-based clinical monitoring agents can deliver gains of up to $21m per drug development programme, as well as an 82-times return on investment (ROI), a study has found.

12th August 2026, Aug. 12 -- focused organisation; H.A.B.I.T. Foundation, an initiative promoting entrepreneurship, innovation and industry-academia collaboration; and AIPFC (Association IP ...

Medable Inc., the leading technology platform for agentic clinical development, today announced a new Tufts Center for the Study of Drug Development (CSDD) analysis showing that an AI clinical ...

JW Pharmaceutical (KRX:001060) announced that the multinational Phase 3 clinical trial of its gout treatment candidate ...

Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III Programs Ramat Gan, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- ...

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum ...

Seattle biotech InduPro has raised $77 million and dosed its first patient in a Phase 1 trial of an experimental cancer drug, ...

Attracted by the data, Takeda paid Protagonist $300 million upfront for rights to the drug candidate in 2024. The partners ...

ProKidney Corp. faces weak Phase 2 rilparencel data and a cash runway only to mid-2027 ahead of pivotal 2027 Phase 3 results.